IPO UPDATE: NeuroDerm's CEO felt well-received, but FibroGen soared
This article was originally published in Scrip
The drug developers NeuroDerm and FibroGen launched initial public offerings on 14 November with two very different results, but even though NeuroDerm's IPO priced below a preliminary range and the stock fell in its first day of trading, CEO Oded Lieberman told Scrip that the Israeli company's Parkinson's disease story "resonated well" with investors.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.